Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1113P represents a processed **pseudogene** copy of the U6 small nuclear RNA (snRNA) gene[4][3]. U6 snRNA itself is an essential RNA component of the spliceosome, which catalyzes pre-mRNA splicing, but the pseudogene copy does not encode a functional RNA or protein and typically results from retrotransposition or genomic duplication events[3]. Pseudogenes like RNU6-1113P lack promoter activity and necessary modifications for functional spliceosome activity and are generally considered nonfunctional relics of genome evolution[3][4]. They are not known to play a role in disease, do not serve as therapeutic drug targets, and do not interact with drugs[4]. There are no recognized therapeutic implications, biomarker uses, or safety concerns associated with this specific pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1113, pseudogene (RNU6-1113P).